December 29, 2021
In Ex parte Price (Appeal 2021-003888), the Patent Trial and Appeal Board (“Board”) reversed the Examiner’s obviousness rejection because of Appellant’s successful showing of unexpected results.
Read more
December 22, 2021
In Ex parte Ruvolo (Appeal No. 2021-001708), the examiner rejected nucleotide claims as anticipated under § 102. The PTAB reversed. Independent claim 12 recited (in part):
Read more
December 13, 2021
AstraZeneca AB v. Mylan Pharm., 2021-1729 (Fed. Cir. Dec. 8, 2021), is a recent decision of the Federal Circuit interpreting the scope of a numerical limitation
Read more
December 3, 2021
In attempting to overcome obviousness rejections, our initial focus often centers on the differences between the cited references and the claimed invention. We do this in
Read more
November 29, 2021
In Ex parte Talamoni (Appeal No. 2020-006553), the Patent Trial and Appeal Board (“Board”) rejected an Examiner’s claim construction overriding the phrase “derived from the reaction
Read more
November 19, 2021
In Ex parte Easson (Appeal 2020-001129), the Patent Trial and Appeal Board (“Board”) reversed the Examiner’s obviousness rejection because the Examiner failed to show the prior
Read more
November 12, 2021
During patent prosecution in the U.S., claims are given their broadest reasonable interpretation consistent with the specification. Ex parte Adel (Appeal No. 2020-006165) is a recent
Read more
November 5, 2021
Ex parte Kuhlmann, is a recent decision of the Patent Trial and Appeal Board (PTAB) addressing prima facie obviousness of a polymer composition. The substance of
Read more
October 29, 2021
Ex parte Lindenblatt, is a recent decision of the Patent Trial and Appeal Board (PTAB) addressing evidence of unexpected results. In Ex parte Lindenblatt, the claim
Read more
October 22, 2021
Recently, the Federal Circuit, in SRI Int’l v. Cisco Sys., 2020-1685 (Fed. Cir. Sep. 28, 2021), clarified the confusion caused by an earlier remand to the
Read more